Stock JSPR JASPER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
20.92 USD +0.77% Intraday chart for Jasper Therapeutics, Inc. -8.12% +165.15%
05-13 Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4 MT
05-07 Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
AQ
Jasper Therapeutics : Corporate Presentation May 2024
PU
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
AQ
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
AQ
Jasper Therapeutics : Corporate Presentation April 2024
PU
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
AQ
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
AQ
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
AQ
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
AQ
Jasper Therapeutics : Corporate Presentation March 2024
PU
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology Annual Meeting
AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
AQ
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
AQ
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
AQ
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology Annual Meeting
AQ
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
AQ
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JSPR Stock
  4. News Jasper Therapeutics, Inc.
  5. Press Releases